Bracebridge Capital, LLC
- SEC CIK
- 0001426486
- Latest filing
- Aug 14, 2026
The latest 13F from Bracebridge Capital, LLC covers Q2 2026 (filed Aug 14, 2026): 27 long positions worth $462.2M. The top 10 holdings make up 96.5% of the portfolio, and the largest is SPDR Gold Trust (GLD) at 50.5%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 4
- Est. +$74.6M
- Added
- 4
- Est. +$14.8M
- Reduced
- 1
- Est. −$117.9M
- Sold out
- 5
- Est. −$24.4M
Top 5 holdings
Share of this quarter's portfolio value
Biggest buys
New and added positions, by estimated amount bought
Largest weight increases
New and added positions, by percentage points of the portfolio gained
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $462.2M
- −$94.0M (−16.9%) vs. prior quarter
- Positions
- 27
- −1 vs. prior quarter
- Top 10 concentration
- 96.5%
- Top 10 as share of value
- Turnover
- 17.6%
- Q2 2026, one quarter
- Average holding period
- 4.1 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $1.01B (Q4 2024)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 27 | $462.2M | GLDUNITCZR | vs. Q1 2026 | SEC |
| Q1 2026 | May 15, 2026 | 28 | $556.2M | GLDUNITTSLA | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 17, 2026 | 27 | $275.2M | GLDUNITADT | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 14, 2025 | 30 | $239.8M | Invesco Exchange Traded FD TUNITALVO | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 31 | $188.0M | iShares Russell 2000 ETFALVOOPTU | vs. Q1 2025 | SEC |
| Q1 2025 | May 15, 2025 | 31 | $158.2M | ALVOOPTUADT | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 14, 2025 | 35 | $1.01B | FBTCiShares Core S&P 500 ETFInvesco Exchange Traded FD T | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 37 | $262.9M | ARKBALVOLiberty Media Corp | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 36 | $199.0M | ARKBALVOLiberty Media Corp | vs. Q1 2024 | SEC |
| Q1 2024 | May 10, 2024 | 38 | $521.8M | ARKBIBITALVO | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 12, 2024 | 38 | $125.2M | ALVODISH Network CORPOSG | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 14, 2023 | 45 | $111.7M | ALVODISH Network CORPLiberty Media Corp | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 14, 2023 | 59 | $125.5M | ALVODISH Network CORPLiberty Media Corp | vs. Q1 2023 | SEC |
| Q1 2023 | May 12, 2023 | 70 | $176.9M | ALVOGOOGMNKTQ | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 10, 2023 | 80 | $263.4M | ALVOLiberty Media CorpMNKTQ | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 1, 2022 | 92 | $273.0M | ALVOLiberty Media CorpOSG | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 8, 2022 | 94 | $306.1M | ALVOLiberty Media CorpASTL | vs. Q1 2022 | SEC |
| Q1 2022 | May 11, 2022 | 93 | $290.8M | Liberty Media CorpASTLDISH Network CORP | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 14, 2022 | 88 | $331.9M | Liberty Media CorpASTLUNIT | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 12, 2021 | 62 | $278.9M | Liberty Media CorpUNITDISH Network CORP | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 12, 2021 | 58 | $251.9M | Liberty Media CorpDISH Network CORPUNIT | vs. Q1 2021 | SEC |
| Q1 2021 | May 17, 2021 | 54 | $201.1M | Liberty Media CorpDISH Network CORPOSG | – | SEC |
13D and 13G filings
Companies where Bracebridge Capital, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
1 company, largest stake first.
Latest filings
13 filings on file made by Bracebridge Capital, LLC or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| FWRDForward Air Corp | Jul 28, 20264:30 PM ET | 13G | 5.10%1.61M shares | New | Jul 23, 2026 | SEC |
| MNKTQKeenova Therapeutics plc | Nov 21, 2024 | 13D/AOld format | – | – | – | SEC |
| EACEdify Acquisition Corp. | Feb 8, 2024 | 13G/AOld format | – | – | – | SEC |
| MNKTQKeenova Therapeutics plc | Nov 17, 2023 | 13D/AOld format | – | – | – | SEC |
| MNKTQKeenova Therapeutics plc | Aug 25, 2023 | 13D/AOld format | – | – | – | SEC |
| MNKTQKeenova Therapeutics plc | Jun 16, 2023 | 13DOld format | – | – | – | SEC |
| EACEdify Acquisition Corp. | Jun 15, 2023 | 13GOld format | – | New | – | SEC |
| QTNTQuotient Ltd | Feb 22, 2023 | 13D/AOld format | – | – | – | SEC |
| QTNTQuotient Ltd | Dec 15, 2022 | 13DOld format | – | New | – | SEC |
| CRXTClarus Therapeutics Holdings, Inc. | Jul 6, 2022 | 13G/AOld format | – | – | – | SEC |
| MNKTQKeenova Therapeutics plc | Jun 27, 2022 | 13GOld format | – | New | – | SEC |
| CRXTClarus Therapeutics Holdings, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| CRXTClarus Therapeutics Holdings, Inc. | Sep 17, 2021 | 13GOld format | – | New | – | SEC |